Comparing TNM7 and TNM6 for Oesophageal Cancer Staging
Author Information
Author(s): Reid T D, Sanyaolu L N, Chan D, Williams G T, Lewis W G
Primary Institution: University Hospital of Wales, Cardiff, UK
Hypothesis
The study aims to determine the influence of the new TNM7 oesophageal cancer system on stage categorisation and survival compared to TNM6.
Conclusion
TNM7 is a better prognostic tool than TNM6 and represents an important advance in staging oesophageal cancer.
Supporting Evidence
- Stage migration occurred in 11.9% of patients when re-classified using TNM7.
- Five-year survival rates for stages I, II, and III were different between TNM6 and TNM7.
- Only the TNM7 prognostic group was significantly associated with survival in multivariable analysis.
Takeaway
Doctors are trying to figure out if a new way to stage oesophageal cancer is better than the old way, and it looks like the new way is more accurate.
Methodology
202 patients with operable oesophageal cancer were re-staged using TNM7 after being originally classified with TNM6.
Potential Biases
Potential bias due to the retrospective nature of the study and the variability in lymph node examination.
Limitations
The study's sample size is relatively small compared to larger multicenter studies, and total lymph node harvests were variable.
Participant Demographics
Median age of participants was 61 years, with 79.7% males and 20.3% females.
Statistical Information
P-Value
P<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website